Passage Bio Inc (NAS:PASG)
$ 0.657 -0.0029 (-0.44%) Market Cap: 40.58 Mil Enterprise Value: -18.43 Mil PE Ratio: 0 PB Ratio: 0.56 GF Score: 36/100

Passage Bio Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript

Mar 31, 2022 / 01:00PM GMT
Release Date Price: $3.1 (+1.64%)
Debjit Chattopadhyay
Guggenheim Securities, LLC - Analyst

Awesome. Good morning and thank you for joining Guggenheim's Genomic Medicine and Rare Disease Conference. I am Debjit Chattopadhyay, one of the therapeutics analysts representing Guggenheim therapeutics team. And my privilege today to host Passage Bio's President and CEO, Dr. Bruce Goldsmith.

Good morning, Bruce, and thank you for your time.

Bruce Goldsmith
Passage Bio, Inc. - President & CEO

Yeah. Good morning. Thanks for having us -- or me, I should say.

Questions & Answers

Debjit Chattopadhyay
Guggenheim Securities, LLC - Analyst

Great. Well, it's been sort of a really rough year for gene therapy in general. Pandemic hasn't obviously made things easier in terms of enrollment stuff. So what are some of the key initiatives within Passage which should limit execution risk as you go forward?

Bruce Goldsmith
Passage Bio, Inc. - President & CEO

Yeah, absolutely. It's a great question

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot